UK markets open in 6 hours 34 minutes

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
14.09+0.61 (+4.53%)
At close: 04:00PM EDT
14.18 +0.09 (+0.64%)
After hours: 07:58PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • B
    This is not good news for millions of people who are looking for hope and help with a serious unmet medical problem. Now, the focus turns to Galectin Therapeutics and their drug Belapectin which in their Stage 2b/3 and has previously shown remarkable results in stopping and reversing compensated NASH Cirrhosis, and an industry leading safety profile.
  • M
    In their last news release when they diluted the stock for a price less than what it was trading for, and most likely they had this information already,it should have been a clue for the investor that the next news wasn’t going to be good. That includes myself but I kept staying in until today
  • K
    The End
  • j
    i took a loss and sold it.
  • k
    Very grateful to anonymous for always keeping it real about the science behind this nash trial. Despite all the slings and arrows. Thankyou
  • S
    Remember that Puny Piper led some of you down this path of destruction.
  • I
    Down $70K. Don't know what to do.
  • K
    R I P
  • F
    LOL, still pumping
  • M
    My guess is possible news after the market closes today tomorrow morning before market opens .
  • g
    Hey ICPT management, what is your definition of late q3 ????? "We expect a topline readout in late Q3 for our Phase 3 REVERSE study in patients with compensated cirrhosis due to NASH"
  • b
    I think it’s wise for everyone to have different t streams of income
  • B
  • o
    Do you invest in the stock market? If so you need to join for their daily emails with must-have watchlists. I don’t know what I would do without them!
  • g
    I think we will be surprised today. Just a hunch .
  • M
    I warned everyone but no one here listened. If you want the real reason for the collapse:

    1. The FDA asked for more safety data because toxicity problems are serious. Not just unbearable itching but also safety signals of liver damage. The FDA can put an end to the entire company at any time, a risk that is weighing heavily on investors.

    2. Even if it is approved there is an invasive biopsy requirement problem:

    From the SVB Leerink Report March 3, 2020
    Make or Break Year for NASH - Key Takeaways from the SVB
    Leerink GHC NASH Panel

    "One key issue highlighted during the discussion was about how to gauge whether
    NASH patients are improving in a commercial setting without doing a liver biopsy.
    Data from the REGENERATE trial, which showed that ~23% of patients experienced a one
    stage reversal of fibrosis after 18 months of treatment, suggest there will be a large
    proportion of patients who are not benefiting from treatment in the real-world over the course
    of 72 weeks. This is an issue for both clinicians, who do not want to subject patients to side
    effects and potential adverse events who are not benefitting, as well as payers, who try to
    avoid reimbursing for drugs where patients are not improving, particularly in the case of
    expensive specialty medicines."

    "We see this as a key area of uncertainty for the commercial market,
    with our panelists unanimously agreeing that this is an issue without a clear, obvious answer
    at this point."
  • A
    If REVERSE data is good, this is a strong buy !! Let’s see the data.
  • E
    At least the risk can be outweighed and seems acceptable by the Reverse phase 3 data.
  • M
    Criminals in charge😡
  • D
    getting Flushed out. is "Dennis" still around, hyping this company to the moon?